Loperamide 1980s, prior to the expiration of US patent on 30 January 1990, McNeil company started to develop Imodium Advanced containing loperamide and simethicone for treating both diarrhea and gas. In March 1997, the company patented such combination. The drug was approved in June 1997 by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet. In November 1993, loperamide was launched as an orally disintegrating tablet based on Zydis technology. Imodium Instant Melts from Johnson & Johnson is currently the only loperamide available in the form of orally disintegrating tablets. In 2013, loperamide in the form of
Medical diagnosis well as the opinion reached thereby) does not necessarily involve elucidation of the etiology of the diseases or conditions of interest, that is, what "caused" the disease or condition. Such elucidation can be useful to optimize treatment, further specify the prognosis or prevent recurrence of the disease or condition in the future. The initial task is to detect a medical indication to perform a diagnostic procedure. Indications include: Even during an already ongoing diagnostic procedure, there can be an indication to perform another, separate, diagnostic procedure for another, potentially concomitant, disease or condition. This may occur as a result of